Revelation Biosciences, Inc. said it may use social media channels to communicate material information and comply with Regulation FD, while clarifying that such disclosures are neither furnished nor filed under the Securities Exchange Act of 1934.
REVB · Revelation Biosciences, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for September 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Revelation Biosciences, Inc. reported $9.1 million in cash as of September 30, 2026 and, based on current operating plans and projections, believes it can fund operations into the second quarter of 2027; nine-month net loss was $9.6 million.
Revelation says cash is insufficient, raising substantial going-concern doubt, with $9.1 million available and a $59.1 million deficit as of September 30, 2026; Nasdaq delisting is possible if market value stays below $5 million for 30 consecutive business days.